Paradigm Biopharmaceuticals (PAR) Short Interest
Paradigm Biopharmaceuticals (ASX:PAR) had 0.02% of shares reported as short positions as of 24 Aug 2026, representing 137,483 shares. Paradigm Biopharmaceuticals operates in the Pharmaceuticals, Biotechnology & Life Sciences industry. Source: ASIC short position report (T+4 delay).
Source: official ASIC short position report, T+4 delay. Methodology · Disclaimer — not financial advice.
Paradigm Biopharmaceuticals
Paradigm Biopharmaceuticals is a late-stage drug development company with the mission to develop and commercialise pentosan polysulfate sodium for the treatment of pain associated with musculoskeletal disorders driven by injury, inflammation, ageing, dege
Short position
Paradigm Biopharmaceuticals (ASX:PAR) has 0.02% of its shares on issue reported as short positions as of 24 Aug 2026, or about 137,483 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has been broadly flat. Its highest recorded short interest was 4.69% in February 2022. PAR is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Weekly context: The 10 most shorted ASX stocks — Week 35, 2026.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4PAR intelligence dossier
Public-source evidence for this company, with industry drill-up links.
- Tax paid and taxable income records
- Government contracts and public money
- Emissions and trade exposure
- Political donations and lobbying links
Short interest history & FAQ
About
website
address
More Pharmaceuticals, Biotechnology & Life Sciences Stocks
Other shorted stocks in this sector
Be the first to discuss PAR
Start a research thread or post the first pulse update